A propos du dénosumab: Anticorps anti-RANKLBRISSAUD, Philippe.Rhumatos. 2012, Vol 9, Num 74, pp 31-35, issn 1771-0081, 5 p.Article

D'orthoclone au dénosumab: L'expansion des anticorps monoclonaux à des fins thérapeutiques = From orthoclone to denosumab, the fast growing market of monoclonal antibodiesBIOT, Jacques; FASANO, Christelle; DOS SANTOS, Céline et al.MS. Médecine sciences. 2009, Vol 25, Num 12, pp 1177-1182, issn 0767-0974, 6 p.Article

Ostéoporose post-ménopausique: Du nouveau dans le domaine des biothérapiesBRIOT, Karine.Rhumatos. 2012, Vol 9, Num 79, pp 240-241, issn 1771-0081, 2 p.Article

Denosumab: mechanism of action and clinical outcomesHANLEY, D. A; ADACHI, J. D; BELL, A et al.International journal of clinical practice (Esher). 2012, Vol 66, Num 12, pp 1139-1146, issn 1368-5031, 8 p.Article

Du nouveau pour inhiber la résorption osseuse: de quoi détrôner le zotédronate ! = New one to inhibit osseous resorption: denosumab demonstrated superiority overzoledronate!DALENC, F; BERGE, Y.La Lettre du sénologue. 2010, Num 48, pp 30-31, issn 1289-2505, 2 p.Conference Paper

Innovations thérapeutiques dans l'ostéoporose (anticorps antisclérostine et denosumab) = Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)QUEMERAIS-DURIEU, M.-A; KERLAN, V; CHABRE, O et al.Annales d'endocrinologie. 2011, Vol 72, issn 0003-4266, S15-S22, SUP1Article

Sclerostin and DKK1 in Postmenopausal Osteoporosis Treated With DenosumabGATTI, Davide; VIAPIANA, Ombretta; FRACASSI, Elena et al.Journal of bone and mineral research (Print). 2012, Vol 27, Num 11, pp 2259-2263, issn 0884-0431, 5 p.Article

Ostéoporose: Remodelage osseux et thérapeutiques anti-ostéoporotiques : ACR 2011: Des Etudes marquantes en avant-premièreCLERC, Dominique.Rhumatos. 2011, Vol 8, Num 73, pp 404-407, issn 1771-0081, 4 p.Article

Late-phase clinical data to support the clinical relevance of RANKL inhibitionADAMI, Silvano; ROUX, Christian.Bone (New York, NY). 2011, Vol 48, issn 8756-3282, S22-S25, SUP1Article

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKLKOSTENUIK, Paul J; NGUYEN, Hung Q; SCULLY, Shelia et al.Journal of bone and mineral research (Print). 2009, Vol 24, Num 2, pp 182-195, issn 0884-0431, 14 p.Article

The relationship of denosumab pharmacology and osteonecrosis of the jawsMALAN, John; ETTINGER, Kyle; NAUMANN, Erich et al.Oral surgery, oral medicine, oral pathology and oral radiology (Print). 2012, Vol 114, Num 6, pp 671-676, issn 2212-4403, 6 p.Article

Denosumab in osteoporosisDIAB, Dima L; WATTS, Nelson B.Expert opinion on drug safety. 2014, Vol 13, Num 2, pp 247-253, issn 1474-0338, 7 p.Article

Effect of Denosumab Treatment on the Risk of Fractures in Subgroups of Women With Postmenopausal OsteoporosisMCCLUNG, Michael R; BOONEN, Steven; HOECK, Hans C et al.Journal of bone and mineral research (Print). 2012, Vol 27, Num 1, pp 211-218, issn 0884-0431, 8 p.Article

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronateKENDLER, D. L; MCCLUNG, M. R; SIDDHANTI, S et al.Osteoporosis international. 2011, Vol 22, Num 6, pp 1725-1735, issn 0937-941X, 11 p.Article

Clinical Efficacy and Safety of Denosumab in Postmenopausal Women with Low Bone Mineral Density and Osteoporosis: A Meta-AnalysisVON KEYSERLINGK, Camilla; HOPKINS, Robert; ANASTASILAKIS, Athanasios et al.Seminars in arthritis and rheumatism. 2011, Vol 41, Num 2, pp 178-186, issn 0049-0172, 9 p.Article

Early clinical data to support the clinical relevance of RANKL inhibitionDIEZ-PEREZ, Adolfo.Bone (New York, NY). 2011, Vol 48, issn 8756-3282, S17-S21, SUP1Article

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMDLEWIECKI, E. Michael; MILLER, Paul D; MCCLUNG, Michael R et al.Journal of bone and mineral research (Print). 2007, Vol 22, Num 12, pp 1832-1841, issn 0884-0431, 10 p.Article

Do RANKL inhibitors (denosumab) affect inflammation and immunity?FERRARI-LACRAZ, S; FERRARI, S.Osteoporosis international. 2011, Vol 22, Num 2, pp 435-446, issn 0937-941X, 12 p.Article

Effects of Denosumab on Fracture and Bone Mineral Density by Level of Kidney FunctionA JAMAL, Sophie; LJUNGGREN, Östen; BOONEN, Steven et al.Journal of bone and mineral research (Print). 2011, Vol 26, Num 8, pp 1829-1835, issn 0884-0431, 7 p.Article

Bone Remodeling in Postmenopausal Women Who Discontinued Denosumab Treatment: Off-Treatment Biopsy StudyBROWN, Jacques P; DEMPSTER, David W; BEIYING DING et al.Journal of bone and mineral research (Print). 2011, Vol 26, Num 11, pp 2737-2744, issn 0884-0431, 8 p.Article

Denosumab for theTreatment of Osteoporosis and Cancer-Related ConditionsLEWIECKI, E. M; BILEZIKIAN, J. P.Clinical pharmacology and therapeutics. 2012, Vol 91, Num 1, pp 123-133, issn 0009-9236, 11 p.Article

Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with OsteoporosisSUTTON, Emily E; RICHE, Daniel M.The Annals of pharmacotherapy. 2012, Vol 46, Num 7-8, pp 1000-1009, issn 1060-0280, 10 p.Article

Traitements des métastases osseuses du cancer = Treatments of metastases in cancerGLIGOROV, Joseph; LAUNAY-VACHER, Vincent; AAPRO, Matti et al.Bulletin du cancer. 2012, Vol 99, Num 3, pp 333-343, issn 0007-4551, 11 p.Article

Osteonecrosis of the Jaw in a Patient on DenosumabAGHALOO, Tara L; FELSENFELD, Alan L; TETRADIS, Sotirios et al.Journal of oral and maxillofacial surgery. 2010, Vol 68, Num 5, pp 959-963, issn 0278-2391, 5 p.Article

Denosumab Reduces the Risk of Osteoporotic Fractures in Postmenopausal Women, Particularly in Those With Moderate to High Fracture Risk as Assessed With FRAXMCCLOSKEY, Eugene V; JOHANSSON, Helena; ODEN, Anders et al.Journal of bone and mineral research (Print). 2012, Vol 27, Num 7, pp 1480-1486, issn 0884-0431, 7 p.Article